FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy

British Journal of Cancer

Volumn 105, Issue 4, 2011, Pages 498-504

  Day, F L ^a   Link, E ^a   Ngan, S ^a   Leong, T ^a   Moodie, K ^a   Lynch, C ^a   Michael, M ^a   Winton, E D ^a   Hogg, A ^a   Hicks, R J ^a   Heriot, A ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Anal cancer; chemoradiotherapy; FDG PET; metabolic response

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FUROSEMIDE; MITOMYCIN;

ADULT; AGED; ANUS CARCINOMA; ANUS SQUAMOUS CELL CARCINOMA; ARTICLE; BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLISM; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; AUSTRALIA; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80051590147     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.274     Document Type: Article

References (41)

1. Ajani JA, Winter KA, Gunderson LL, Pederson J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TZ, Willett C (2008) Fluorouracil, mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal. JAMA 299: 1914-1921 (Pubitemid 351574921)
2. Ajani JA, Winter KA, Gunderson LL, Pederson J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG (2010) Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the Intergroup Trial (RTOG 98-11). Cancer 116: 4007-4013
3. Akbari RP, Paty PB, Guillem JG, Weiser MR, Temple LK, Minsky BD, Saltz L, Wong WD (2004) Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. Dis Colon Rectum 47: 1136-1144 (Pubitemid 38857060)
4. Andrade RS, Heron DE, Degirmenci B, Filho PAA, Branstetter BF, Seethala RR, Ferris RL, Avril N (2006) Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 65: 1315-1322 (Pubitemid 44425218)
5. Benard F, Smith R, Hustinx P, Karp K, Alavi A. (1999) Clinical evaluation of processing techniques for attenuation correction with 137-Cs in whole-body PET imaging. J Nucl Med 40: 1257-1263 (Pubitemid 29385632)
6. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A (2009) Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum 52: 624-631
7. Borzomati D, Valeri S, Ripetti V, Vincenzi B, Rabitti C, Persichetti P, Valentini V, Trodella L, Caricato M, Coppola R (2005) Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication? Hepatogastroenterology 52: 780-784 (Pubitemid 40834604)
8. Chapet O, Gerard J-P, Riche B, Alessio A, Mornex F, Romestaing P (2005) Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys 63: 1316-1324 (Pubitemid 41628024)
9. Cotter SE, Grigsby PW, Siegel BA, Dehdashti F, Malyapa RS, Fleshman JW, Birnbaum EH, Wang X, Abbey E, Tan B, Kodner IJ, Hunt SR, Lowney JK, Mutch MG, Dietz DW, Myerson RJ (2006) FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 65: 720-725 (Pubitemid 43795859)
10. de Winton E, Heriot AG, Ng M, Hicks RJ, Hogg A, Milner A, Leong T, Fay M, MacKay J, Drummond E, Ngan SY (2009) The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer 100: 693-700
11. Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Houry S, Gallot D, Parc R, Huang R, Qu S-H, Huart J, Pene F, Schlienger M (2003) Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Onc Biol Phys 56: 1259-1273 (Pubitemid 36842877)
12. Duong C, Hicks R, Weih L, Drummond E, Leong T, Michael M, Thomas R (2006) FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in esophageal cancer. Eur J Nucl Med Mol Imaging 33: 770-778 (Pubitemid 43979684)
13. Ellerhorn DI, Enker WE, Quan SH (1994) Salvage abdominoperineal resection following combined chemotherapy and radiotherapy for epidermoid carcinoma of the anus. Ann Surg Oncol 1: 105-110
14. Frisch M, Glimelius B, van den Brule AJ, Wohlfahrt J, Meijer CJ, Walboomers JM, Goldman S, Svensson C, Adami HO, Melbye M (1997) Sexually transmitted infection as a cause of anal cancer. N Engl J Med 337: 1350-1358 (Pubitemid 27467769)
15. Hicks RJ (2009) Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 50(Suppl): 31S-42S
16. Holly EA, Whittemore AS, Aston DA, Ahn DK, Nickoloff BJ, Kristiansen JJ (1989) Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 81: 1726-1731 (Pubitemid 19275911)
17. Iagaru A, Kundu R, Jadvar H, Nagle D (2009) Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma. Hell J Nucl Med 12: 26-29
18. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR (2004) Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 101: 281-288 (Pubitemid 38890830)
19. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 25: 571-578 (Pubitemid 350002965)
20. Kalff V, Ware R, Heriot A, Chao M, Drummond E, Hicks RJ (2009) Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy. Int J Radiat Oncol Biol Phys 74: 60-66
21. Kidd EA, Dehdashti F, Siegel BA, Grigsby PW (2010) Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol 95: 288-291
22. Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, Klutmann S, Knapp WH, Zijlstra JM, Bockisch A, Weckesser M, Lorenz R, Schreckenberger M, Bares R, Eich HT, Mueller RP, Fuchs M, Borchmann P, Schicha H, Diehl V, Engert A (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112: 3989-3994
23. MacManus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, Ball DL (2003) Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small cell lung cancer. J Clin Oncol 21: 1285-1292 (Pubitemid 46606405)
24. Mikhaeel NG, Timothy AR, O'Dpherty MJ, Hain S, Maisey MN (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma: comparison with CT. Leuk Lymphoma 39: 543-553 (Pubitemid 32162393)
25. Moskowitz CH, Zelenetz A, Schoder H (2010) An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. J Natl Compr Canc Netw 8: 347-352
26. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW (2006) Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol 14: 478-483
27. Myerson RJ, Outlaw ED, Chang A, Birnbaum EH, Fleshman JW, Grigsby PW, Kodner IJ, Malayapa RS, Mutch MG, Parikh P, Picus J, Tan BR (2009) Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Onc Biol Phys 75: 428-435
28. Nayak JV, Walvekar RR, Andrade RS, Daamen N, Lai SY, Argiris A, Ferris RL, Johnson JT, Branstetter BF (2007) Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope 117: 2129-2134 (Pubitemid 351339585)
29. NCCN Clinical Practice Guidelines in Oncologyt-V.1.2010 (www.nccn.org)
30. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A (2008) Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol 87: 376-382
31. Nigro M, Vaitkevicius V, Considine S (1974) Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 17: 354-356
32. Nilsson PJ, Svensson C, Goldman S, Glimelius B (2002) Salvage abdominoperineal resection in anal epidermoid cancer. Br J Surg 89: 1425-1429
33. Olivatto LO, Araujo CM, Vilhena B, Meton F, Bezerra M, Erlich F, Castro L, Ferreira CG (2010) Phase I study of cetuximab (CET) in combination with 5-FU, cisplatin (CP), and radiotherapy (RT) in patients with locally advanced squamous cell anal canal carcinoma (LASACC). 2010 Gastrointestinal Cancers Symposium. ASCO GI Congress 2010. Abstract No. 492
34. Ong SC, Schoder H, Lee NY, Patel SG, Carlson D, Fury M, Pfister DG, Shah JP, Larson SM, Kraus DH (2008) Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 49: 532-540 (Pubitemid 351520600)
35. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM (1998) High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 12: 495-503 (Pubitemid 28116159)
36. Porceddu SV, Jarmolowski E, Hicks RJ, Ware R, Weih R, Rischin D, Corry J, Peters LJ (2005) Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 27: 175-181 (Pubitemid 40315765)
37. Robinson D, Coupland V, Moller H (2009) An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br J Cancer 100: 527-531
38. Sato H, Koh P-K, Bartolo DCC (2005) Management of anal canal cancer. Dis Colon Rectum 48: 1301-1315 (Pubitemid 40897880)
39. Scherrer A, Reboul F, Martin D, Dupuy JC, Menu Y (1990) CT of malignant anal canal tumors. Radiographics 10: 433-453
40. Schwarz JK, Siegel BA, Dehdashti F, Myerson RJ, Fleshman JW, Grigsby PW (2008) Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 71: 180-186 (Pubitemid 351492591)
41. Trautmann TG, Zuger JH (2005) Positron emission tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 7: 309-313